Theranostics Licenses Biomarker Microdissection Tech from NIH | GenomeWeb
NEW YORK (GenomeWeb News) – Theranostics Health said today it has licensed proteomic biomarker discovery technology from the National Institutes of Health that was developed by the company’s founders.
 
The Rockville, Md.-based company’s core technology, Reverse Phase Protein Microarray combined with Laser Capture Microdissection, was developed by company co-founders Emanuel Petricoin and Lance Liotta.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: genetic study of breast cancer in Egyptian families, mutations linked to cleft lip and palate, and more.

Council Bluffs, Iowa, schools are encouraging more girls to pursue STEM courses, according to the Associated Press.

Because of new open-access requirements, Gates Foundation-funded researchers can't publish in some top journals, Nature News reports.

In Science this week: deletion of one microRNA allows pluripotent stem cells to form embryonic and non-embryonic lineages, and more.